Read this
Reading File
Running Command
Here is a full summary of the document:
PET-CT Report - Clinical Correlation & Action Plan
Patient: Mr. K Bhawaj Raj, 25-year-old male
Diagnosis: Known Langerhans Cell Histiocytosis (LCH), post-chemotherapy (last chemo 2025)
Scan date: 09-May-2026 | Compared against prior PET-CT from 07/06/2025
What the PET-CT Shows
Good news - no systemic spread:
- Brain, lungs, liver, spleen, pancreas, bone marrow: all clear
- No lymphadenopathy, no abdominal/pelvic disease
- Raj remains in the low-risk stratum (no risk-organ involvement)
Critical finding - disease reactivation:
| Lesion | SUVmax | Significance |
|---|---|---|
| Right frontal bone | 16.1 | Markedly elevated - highly active disease |
| Left posterior parietal bone | Not specified | New - not on prior scan |
| Left 3rd rib (anterior) | 6.32 | New extracranial osseous lesion |
An SUVmax of 16.1 is at the high end for LCH bone lesions (typical range 5-15), indicating very aggressive metabolic activity. The MRI from 05-May-2026 had already shown the right frontal and occipital lesions with soft tissue infiltration; the PET confirms active metabolism and reveals new lesions.
Clinical Interpretation
Pattern: Multifocal bone LCH (skull x2 + rib) - post-chemotherapy reactivation
Risk: Low-risk relapse by classification (no risk-organ involvement), but multifocal, involving a special site (skull with prior diabetes insipidus), and occurring after first-line chemo - requiring prompt action.
Reactivation rates in LCH run 20-50%, consistent with this presentation.
Action Plan (5 Steps)
Step 1 - Urgent Biopsy
Biopsy the left 3rd rib (most accessible) or left posterior parietal lesion to:
- Confirm active LCH vs. infection, reactive change, or secondary malignancy
- Test for BRAF V600E mutation (~55% of LCH cases carry this)
- If BRAF-negative: run MAP2K1/MAPK pathway panel
This is the most important immediate step - the BRAF result dictates the entire treatment path.
Step 2 - Simultaneous Molecular Workup
- BRAF V600E (tissue + liquid biopsy/cfDNA)
- Full MAPK panel
- CBC, LFTs, LDH, ferritin
- Urine osmolality + serum sodium baseline (for DI monitoring)
Step 3 - Treatment Decision
- If BRAF V600E positive: Vemurafenib or Dabrafenib (± Trametinib). Strong response rates in relapsed/refractory LCH, though relapse on discontinuation is near-universal - likely requiring long-term therapy. Tovorafenib (panRAF inhibitor) is an emerging option.
- If BRAF negative (MAPK mutated): Cobimetinib (MEK inhibitor, FDA-approved for histiocytic neoplasms) or Trametinib/Binimetinib.
- If BRAF/MAPK negative or targeted therapy unavailable: Cladribine (~80% ORR, first choice), Cladribine + Cytarabine (CLARAC), or Clofarabine (third-line).
Step 4 - Local Therapy
The right frontal lesion (SUVmax 16.1, 23 mm, soft tissue infiltration) may warrant low-dose involved-field radiotherapy (6-10 Gy) as a bridge or adjunct - not as sole treatment given multifocal disease.
Step 5 - Diabetes Insipidus (DI) Monitoring
- Monitor serum sodium daily during chemo; use only isotonic IV fluids
- Avoid vincristine if possible (SIADH risk); if used, monitor sodium aggressively
- Continue DDAVP at current dose - do not adjust empirically
- Check morning urine + serum osmolality at each cycle start
Bottom Line
This is a confirmed post-chemotherapy LCH reactivation at three new sites (bilateral skull + left rib). No risk-organ involvement preserves a favorable prognosis. Immediate priority: biopsy + BRAF V600E testing. The result determines whether he proceeds to targeted therapy (preferred) or salvage chemotherapy, with DI management running throughout.
Sources cited: Goldman-Cecil Medicine (2025) pp. 1783-84; Abla O., Hematology ASH 2023 [PMID 38066856]; Lin & Cao, Target Oncol 2024 [PMID 38990463]
This is biopsy report. What does it interpret and what should be the treatment plans
Running Command
Reading File
Finding Sources
Searching PubMed
Langerhans cell histiocytosis BRAF negative treatment salvage
Searching PubMed
Langerhans cell histiocytosis cladribine cytarabine relapsed refractory
Reading File
Finding Sources
Searching PubMed
Langerhans cell histiocytosis BRAF negative MAP2K1 MEK inhibitor treatment
Finding Sources
Searching PubMed
Langerhans cell histiocytosis relapsed refractory cladribine MEK inhibitor outcome
Finding Sources
Searching PubMed
LCH BRAF wild-type MAPK mutation cobimetinib trametinib histiocytosis
Reading File
I now have all the information needed for a comprehensive analysis. Here is the full clinical correlation and action plan.
Biopsy Report Interpretation - Oncomine Focus Assay (52-Gene Panel)
Report date: 03 Jun 2026 | Lab: Yashoda Molecular Diagnostics, Hyderabad
Sample: FFPE tissue block | Tumor cellularity: 30%
Platform: Ion S5 Plus | Average coverage depth: 1,299x | Target base at 500x: 97.38%
What the Result Says
"No clinically significant gene variants identified in the tested panel."
This is a BRAF V600E-negative, MAPK panel-negative result across a comprehensive 52-gene assay covering:
- DNA sequence variants: including BRAF, MAP2K1, MAP2K2, KRAS, NRAS, RAF1, and all other major MAPK pathway genes
- Copy number variations: including BRAF, EGFR, MET, and 18 others
- Gene fusions: including BRAF, RAF1, NTRK1-3, FGFR1-3, and ALK
In plain terms - no actionable mutation was detected in any of the 52 genes screened. This rules out:
- BRAF V600E (found in ~55% of LCH) - not present
- MAP2K1/MAP2K2 mutations - not present
- Other MAPK pathway alterations (KRAS, NRAS, RAF1) - not present
- NTRK, FGFR, ALK fusions - not present
Important Caveat
The tumor cellularity is only 30% - at the lower threshold of reliable detection. The assay's sensitivity floor is 5% for SNVs and 10% for indels. Combined with a 30% cellularity, low-allele-frequency mutations are at real risk of being missed. This is not a guaranteed negative - it is a negative within the assay's limits.
Additionally, the primary tumor site is listed as "Lung" - but Raj's disease is bone-based LCH. This labeling likely reflects the FFPE block submission code and should be confirmed with the pathologist, as it does not change the genomic interpretation.
What This Means for Treatment
With BRAF V600E negative and the full MAPK panel negative, Raj now falls into the pathway where targeted therapy is not directly available via the standard vemurafenib/dabrafenib route. The treatment strategy shifts as follows:
Treatment Plan - BRAF/MAPK-Negative Relapsed Multifocal Bone LCH
Option 1 - Salvage Chemotherapy (First Choice)
Cladribine (2-CdA) monotherapy
- Standard first-choice salvage for relapsed/refractory LCH
- Overall response rate ~81% in adults (Harrison's, p. 925; Goldman-Cecil, p. 1784)
- Dosing: 5 mg/m² IV daily x 5 days, every 4 weeks x 4-6 cycles
- Well tolerated; myelosuppression is the main toxicity
Cladribine + Cytarabine (CLARAC regimen)
- Preferred over cladribine alone for more aggressive relapse or prior cladribine failure
- Goldman-Cecil (2025): "Cladribine and high-dose cytarabine may be effective in relapsed/refractory settings."
- Applicable here given: multifocal disease, post-first-line reactivation, high SUVmax (16.1)
Cytarabine monotherapy (high-dose)
- Alternative if cladribine not tolerated
Clofarabine
- Reserved as third-line if above fail
Option 2 - MEK Inhibitor (Consider Despite "Negative" Panel)
Even with a panel-negative result, MEK inhibitors remain a clinical option in LCH because:
- Assay limitations - 30% tumor cellularity with possible subthreshold mutations not detected
- Known biology - virtually all LCH is driven by MAPK pathway activation, even if the specific mutation is not detectable by a 52-gene panel. Rare or atypical MAPK alterations may lie outside panel coverage.
- Trametinib has shown 71% response rate in histiocytic neoplasms including BRAF-negative cases with other MAPK pathway mutations (Harrison's, p. 925)
- Cobimetinib is FDA-approved for histiocytic neoplasms without BRAF V600E
This should be discussed with the treating oncologist and possibly a molecular tumor board. Empirical MEK inhibitor trial is a reasonable consideration if salvage chemo fails or is poorly tolerated.
Option 3 - Local Therapy (Adjunct, Not Sole Treatment)
The right frontal bone lesion (SUVmax 16.1, 23 mm, soft tissue extension on MRI) is the dominant aggressive site. Consider:
- Low-dose involved-field radiotherapy: 6-10 Gy to the right frontal lesion
- Indicated if soft tissue extension threatens neurovascular structures or causes pain
- Use as a bridge to systemic therapy, not as standalone treatment given multifocal disease
Recommended Immediate Steps
| Priority | Action |
|---|---|
| Urgent | Confirm BRAF V600E by an orthogonal method - specifically VE1 immunohistochemistry (IHC) on the FFPE block. NGS can miss this if tumor cellularity is marginal. |
| Urgent | Repeat liquid biopsy/cfDNA for BRAF V600E and MAPK panel - circulating tumor DNA may detect mutations missed in a low-cellularity solid biopsy |
| Start planning | Begin Cladribine ± Cytarabine as salvage chemotherapy - do not wait indefinitely for mutation confirmation given active, high-metabolic disease |
| Concurrent | Initiate sodium + DI monitoring protocol (DDAVP continuation, daily Na+ during infusions, isotonic IV fluids only) |
| Consider | Referral to a histiocytosis center of excellence or molecular tumor board for MEK inhibitor eligibility discussion |
Summary
The Oncomine 52-gene panel found no BRAF V600E and no actionable MAPK mutation, placing Raj in the BRAF/MAPK-negative relapsed LCH category. However, the 30% tumor cellularity introduces meaningful uncertainty - orthogonal BRAF testing (IHC) and cfDNA liquid biopsy are strongly recommended before closing the door on targeted therapy. In parallel, Cladribine-based salvage chemotherapy (CLARAC preferred given aggressive relapse) should be initiated promptly given the active multifocal disease with SUVmax 16.1. MEK inhibitor therapy remains on the table empirically if chemotherapy fails. Local radiotherapy to the dominant right frontal lesion is an appropriate adjunct.
Sources: Goldman-Cecil Medicine (2025), pp. 1783-84; Harrison's Principles of Internal Medicine 22E (2025), p. 925
Is this good or bad. Mutation is better or no mutation is better. Is there any tablet treatment available?
This is a great practical question that families often ask. Let me give a clear, honest answer.
Is "No Mutation Found" Good or Bad?
In most cancers, finding no mutation is good news. In LCH, it is more complicated - and somewhat counterintuitive.
For LCH specifically: Having the BRAF V600E mutation is actually better from a treatment standpoint.
Here is why:
| BRAF V600E Positive | BRAF V600E Negative (Raj's result) | |
|---|---|---|
| Targeted therapy available? | YES - vemurafenib, dabrafenib (oral tablets) | No direct targeted drug approved |
| How it works | One tablet twice a day, taken at home | Needs IV chemotherapy infusions in hospital |
| Response rate | Very high (~80-90%) | Lower (~60-80% with chemo) |
| Side effects | Generally milder - rash, joint pain, fatigue | Stronger - bone marrow suppression, infection risk |
| Convenience | Oral, outpatient | IV drip, hospital visits |
| Long-term remission | Often needs to continue long-term (stops working if stopped) | Can sometimes achieve lasting remission |
So paradoxically, BRAF-positive patients have it easier in terms of treatment - they get a daily tablet instead of IV chemotherapy.
Is There a Tablet Treatment for Raj?
Currently, no approved oral tablet is available for confirmed BRAF-negative LCH. However, there are important nuances:
1. The result may not be the final word
The biopsy had only 30% tumor cells - borderline for reliable testing. There is a real chance the mutation is present but was missed. Two additional tests are recommended:
- VE1 immunohistochemistry (IHC) - a simpler stain on the same biopsy block
- Liquid biopsy (blood test) - looks for tumor DNA circulating in the blood
If either comes back positive, tablet treatment (vemurafenib or dabrafenib) becomes available immediately.
2. MEK inhibitor tablets - a possible option even now
Even without BRAF mutation, there are oral MEK inhibitor tablets:
| Drug | Form | Status |
|---|---|---|
| Cobimetinib | Oral tablet | FDA-approved for histiocytic tumors without BRAF V600E |
| Trametinib | Oral tablet | Used in BRAF-negative histiocytic disease, ~71% response rate |
| Binimetinib | Oral tablet | Being studied |
These work on the same pathway (one step downstream of BRAF). They are genuine oral tablet options that the doctor can consider even with a negative BRAF result.
3. Tovorafenib (newest option)
A newer pan-RAF inhibitor tablet currently showing promising results in relapsed/refractory LCH - still emerging but worth asking about in a specialist center.
Bottom Line for Raj's Family
- Not having a mutation is not ideal in LCH because it closes the easy tablet-treatment door
- However, it does not mean no tablet treatment - MEK inhibitor tablets (cobimetinib, trametinib) are a real option and should be actively discussed with the oncologist
- Before accepting "no mutation," two more tests should be done - IHC staining and a blood liquid biopsy - because the original test had borderline tumor cellularity
- If those also come back negative, the starting treatment will be IV chemotherapy (cladribine), which is effective but requires hospital visits
- The disease is still low-risk in terms of organ involvement - no liver, spleen, or bone marrow disease - which means the prognosis remains favorable regardless of mutation status
The most important next conversation with the treating doctor is: "Can we do VE1 IHC and a liquid biopsy before starting chemotherapy, and can we consider cobimetinib or trametinib as oral options?"
Braf mutation
Finding Sources
Searching PubMed
BRAF V600E Langerhans cell histiocytosis vemurafenib dabrafenib
Finding Sources
Reading Article
Here is a complete, plain-language explanation of BRAF mutation - what it is, what it does, and what it means for Raj.
What is BRAF?
BRAF is a normal gene that every human has. It produces a protein called B-Raf, which acts like a switch inside cells - it tells cells when to grow and divide.
In a healthy body, this switch turns ON when needed and turns OFF when done. It is part of a chain of signals called the RAS → RAF → MEK → ERK pathway - think of it like a relay race where each runner passes the baton to the next.
Normal cell:
Growth signal → RAS → BRAF → MEK → ERK → Cell grows → STOPS
What is the BRAF V600E Mutation?
The V600E mutation is a tiny spelling error in the BRAF gene - specifically at position 600, where the amino acid Valine (V) is incorrectly swapped for Glutamic acid (E).
This one small change has a massive consequence:
Mutated cell:
No signal needed → BRAF stuck ON permanently → MEK → ERK → Cell keeps growing FOREVER
The BRAF protein gets permanently locked in the "ON" position, even with no outside instruction. The cell divides uncontrollably. This is how LCH (and several other cancers) is driven in ~55% of cases.
Why Does This Matter for Treatment?
Because if you know the switch is broken and stuck ON - you can make a drug that specifically blocks that broken switch.
That is exactly what BRAF inhibitors do:
| Drug | Trade Name | Form | How it works |
|---|---|---|---|
| Vemurafenib | Zelboraf | Oral tablet | Fits into the mutated BRAF protein and blocks it |
| Dabrafenib | Tafinlar | Oral capsule | Same mechanism, slightly different profile |
| Dabrafenib + Trametinib | Tafinlar + Mekinist | Two oral tablets | Blocks BRAF + also blocks MEK (the next step), better together |
These are taken at home, by mouth, daily - no IV drips, no hospital admissions for chemotherapy.
BRAF Mutation in LCH - Key Facts
| Fact | Detail |
|---|---|
| How common in LCH? | ~55% of all LCH patients carry it |
| What does it predict? | Higher disease activity, more reactivation risk - but also better targeted therapy options |
| Response to BRAF inhibitors | Very high - 80-90% of patients respond |
| Does it cure? | Usually not permanently - disease often returns when the tablet is stopped, so long-term/continuous treatment is likely needed |
| Side effects of the tablet | Skin rash, joint pain, sun sensitivity, fatigue - generally manageable |
So Why Was Raj's Test Negative?
There are three possibilities:
- Raj genuinely does not have the mutation (~45% of LCH patients are truly BRAF wild-type) - in which case targeted therapy is not available this way
- The mutation is present but was missed - the biopsy had only 30% tumor cells, which is at the margin of reliable detection. Low tumor cell content means a real mutation can be below the assay's detection limit (5% threshold for SNVs)
- A different MAPK mutation is driving his disease - MAP2K1 or others - which responds to MEK inhibitors instead
What Should Be Done Next (BRAF-specific)
| Test | Why |
|---|---|
| VE1 immunohistochemistry (IHC) on the same FFPE block | A simple antibody stain that directly detects the mutant BRAF protein - orthogonal to NGS, not affected by low cellularity in the same way |
| Liquid biopsy / cfDNA (blood test) | Detects BRAF V600E circulating in the blood from all tumor sites - can catch what a single-site biopsy misses |
These two tests together cost less than one cycle of chemotherapy and could completely change the treatment plan. If either is positive, Raj becomes eligible for the tablet (vemurafenib/dabrafenib) immediately.
Simple Summary
- BRAF is a normal gene; BRAF V600E is a mutation that locks a cell growth switch permanently ON
- In LCH, having this mutation is not bad luck in terms of treatment - it opens the door to oral targeted tablets
- Raj's current test said "no mutation" but the test may not be fully reliable due to low tumor cell content
- Two more simple tests (IHC on the biopsy block + blood liquid biopsy) should be done urgently before concluding no mutation exists
- If confirmed negative, MEK inhibitor tablets (cobimetinib, trametinib) are still a potential oral option via a different but related mechanism
This is a shared conversation. Sign in to Orris to start your own chat.